Alison Dennis, Partner, Life Sciences

Alison Dennis, Partner, Life Sciences, Fieldfisher

I am a partner in Fieldfisher's 60+ strong life sciences and healthcare sector group.  I enjoy being part of a team that includes so many recognised specialists in their field, helping clients to resolve issues or complete  transactions.

I have extensive experience in drafting and negotiating agreements with particular emphasis on the protection and exploitation of intellectual property rights through a variety of different structures, including contractual joint ventures, patent and know-how licences, co-promotion and co-marketing agreements.  I frequently advise life sciences focused companies on their acquisitions: carrying out due diligence on the ownership of IP rights and drafting documents to clarify ownership.

I help clients to resolve issues with regulatory bodies, including the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) and regularly assist them to understand the regulations applicable to their products as well as to comply with the intricacies of the European Union clinical trials legislation.

I have a particular focus on working with medical device companies and helping them to sell their products in the EU and beyond in compliance with the different codes and laws that apply, providing practical solutions to achieve compliance with medical device codes and laws through policies, contract templates and practices with international application. This work includes compliance with anti-bribery provisions as well as advertising laws.  I am deputy chair and an active participant in the compliance and legal working groups of the Association of British Healthcare Industries (ABHI).  As a result, I am thoroughly immersed in the medical devices industry and the legal developments affecting it, both in the US and Europe.

I am the author of the UK and EU chapters and co-editor with Bar & Karrer AG of:  Distribution and Marketing of Drugs, Jurisdictional Comparisons, The European Lawyer Reference Series, January 1, 2013, an analysis of laws relating to the distribution and marketing of drugs in 26 countries and in the EU as well a the author of the EU chapter for the Commercialisation of Health book in the same series.  See also my publication on What Pharmaceutical Companies Need to Know about the UK Bribery Act, August 2010 in RAJ Pharma.

According to Chambers, my clients appreciate me for my 'ability to strike the right balance between pragmatism and theoretical knowledge', for being 'practical, articulate and intuitive' and being an 'exceptionally bright and personable figure' who commands 'a great understanding of her clients' business needs'.

Chambers UK 2015 says "she is very cerebral and very careful, and considers everything"

I speak fluent French, a skill that I use from time to time in negotiations and in giving talks on my specialist areas.

Chamber UK 2015 Ranked Individual    Legal 500 2014 recommended lawyer    Super Lawyers 2014

Alison's offices


Alison's activity stream